Poliovaccine
AssigneeSecretary of State for Health and Social Care, Ministerial Correspondence and Public Enquiries, Department of Health and Social Care
InventorAndrew Macadam
Life of this patent
Estimating the term…
Abstract
The invention provides poliovirus like particles, which comprise stabilised empty poliovirus capsids that retain their native antigenic properties. The invention also provides methods of identifying mutations useful in the production of such poliovirus like particles, methods of producing such poliovirus like particles and the use of such poliovirus like particles in methods of vaccinating against poliovirus.
Claims11
A poliovirus-like particle (VLP) which comprises modifications relative to the poliovirus particle from which the VLP is derived which stabilise the VLP, wherein:
- (a) the VLP is derived from a type 1 poliovirus and comprises the following mutations:
- R4018G, T2025A, D2057E, L3119M, Q3178L and H1248P;
- (b) the VLP is derived from a type 2 poliovirus and comprises the following mutations:
- L3085F, Q3178L, T1041I, F1134L and Y1159F;
- (c) the VLP is derived from a type 2 poliovirus and comprises the following mutations:
- I4057V, D2057A, Q3178L, V1107I, F1134L and V1183L;
- or
- (d) the VLP is derived from a type 3 poliovirus and comprises the following mutations:
- T4067A, L20181, L2215M, D2241E, H3019Y, L3085F, T1105M and F1132L;
- wherein the modifications relative to the poliovirus particle from which the VLP is derived stabilises the native-antigenic conformation of the poliovirus capsid.
Dependencies are inferred from the claim text.